The cold and cough preparations refer to the medications that are used to treat cold and cough. The drugs for the treatment of cold and cough act on the receptors to which the virus causing the infection gets attached, by antagonizing the action of the receptors and killing the viral infection, thereby reducing congestion by lysing the mucus and dilating the bronchioles constricted by the mucus deposition. The main types of drugs in cold and cough preparations are antihistamines, expectorants, bronchodilators, decongestants, antibiotics, and others. Antihistamines are drugs or other compounds that block the physiological effects of histamine and are used to treat allergies in particular. The different types include bronchodilators, anticholinergic, and pulmonary antihypertensives. The several dosage types include oral syrups, tablets or pills, nasal drops, lozenges, and others and are distributed through various channels such as hospital pharmacies, retail pharmacies, and drug stores. The cold and cough preparations market research report is one of a series of new reports from The Business Research Company that provides cold and cough preparations market statistics, including cold and cough preparations industry global market size, regional shares, competitors with a cold and cough preparations market share, detailed cold and cough preparations market segments, market trends and opportunities, and any further data you may need to thrive in the cold and cough preparations industry. This cold and cough preparations market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global cough and cold preparations market size will grow from $66.75 billion in 2022 to $70.37 billion in 2023 at a compound annual growth rate (CAGR) of 5.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global cough and cold preparations market size is expected to grow to $84.02 billion in 2027 at a CAGR of 4.5%. The rising incidence of allergies is expected to fuel the growth of the cough and cold preparations market in the forecast period. There are many respiratory allergies such as pollen, dust, mold, and pet allergies; these allergies are caused due to contaminated outdoor and indoor air. Cough and cold preparations are consumed for treating allergies, which cause cough and cause issues in the respiratory tract. For instance, according to the European Academy of Allergy and Clinical Immunology, a non-profit organization for European clinicians, researchers, and allied health professionals, by 2025, 1 in every 3 people in the European Union is expected to be affected by allergies. Thus, the increase in the incidence of respiratory allergies will bolster the demand for cough and cold preparations, positively affecting the growth of the market. Threat from substitute products such as generic and counterfeit drugs is significantly restraining the global cold and cough preparations market. Pharmaceutical companies invest a large sum of money in the drug development process. Once a drug candidate is developed and approved by the regulatory authorities, companies patent their inventions to protect their intellectual property. During the patency period, the company holding the patent holds exclusivity for manufacturing and distribution. Post expiration of patency, generic versions of the drugs is manufactured by other companies. The prices of the generics are very low in comparison to the original brand of the drug. According to an article by Alpha InvesCo., a new FDA-approved blockbuster drug that netted $100 million a year in profit during its patent protection duration could become one that earns only $1 million a year in profit overnight after losing its patent. Additionally, there is a major international problem with counterfeit drugs. The best of these counterfeits duplicates a real drug’s formula and sells it at a lower price, which hurts pharmaceutical companies' profits. Moreover, counterfeits made with low-grade materials can destroy the reputations of legitimate products, thus affecting the growth of the market. Advancements in technologies are driving the global pharmaceutical sector including cold and cough preparations. According to a global life sciences report by Deloitte, the adoption of AI, robotic automation, the Internet of Medical Things (IoMT), blockchain, DIY diagnostics, virtual care, mobility in drug delivery and clinical trials, genomics, next-generation therapies, cloud computing, Real-World Evidence (RWE), and data-driven precision medicine are the major technologies driving the life sciences sector. AI technology is being used in diagnoses, treatment planning, patient monitoring, and drug discovery. The IoMT is allowing new business models to emerge and enhancing customer experiences. Pharmaceutical companies are also increasingly using biomarkers in the drug development process to reduce the time taken to bring the product into the market. Biomarkers are biological indicators that are objectively measured and evaluated for biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention. The cold and cough preparations market is regulated by authorities such as the Food and Drug Administration in the US. For instance, the Food and Drug Administration (FDA) restricted the use of codeine in children. Codeine is approved to treat pain and cough but this medicine carries serious risks, including slowed or difficult breathing, and can be potentially fatal. This risk is greater in children younger than 12 years but the use of codeine should also be limited in some older children. Single-ingredient codeine is FDA-approved only for use in adults. FDA is also recommending against the use of codeine in breastfeeding mothers due to possible harm to their infants. Major players in the cold and cough preparation market are AstraZeneca, Bayer, Blackmores Limited, Dabur, GlaxoSmithKline, Himalaya Global Holdings, Hyland's, Johnson & Johnson, Novartis and Perrigo Company. North America was the largest region in the cold and cough preparation market in 2022. Middle East is expected to be the fastest-growing region in the global cough and cold preparations market during the forecast period. The regions covered in the global cold and cough preparation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cold and cough preparations market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The cold and cough preparations market consists of sales of dextromethorphan, guaifenesin, and phenylephrine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cough and cold preparations market is segmented - 1) By Type: Bronchodialators, Anticholinergic, Pulmonary Antihypertensives 2) By Drug Type: Antihistamines, Expectorants, Bronchodilators, Decongestants, Antibiotics, Other Types 3) By Dosage Type: Oral Syrups, Tablets/Pills, Nasal Drops, Lozenges, Other Dosage Types 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores

The anti-obesity drugs market consists of sales of anti-obesity drugs and related services. This industry includes establishments that produce pharmacological agents that reduce or control overweight.

The global antiobesity market was valued at about $1.3 billion in 2018 and is expected to grow to $3.44 billion at a CAGR of 27.5% through 2022.

The anti-obesity drugs market has been geographically segmented into North America, Western Europe, APAC, Eastern Europe, South America and Middle East & Africa. The North American market is the largest market for anti-obesity drugs and is expected to continue to be the largest market during the forecast period.

Obesity is a major public health concern globally. Globally, prevalence rate of obesity is increasing every year. According to WHO, in 2016, more than 1.9 billion adults over the age of 18 years were overweight of which over 650 million were obese. This can be attributed to increased consumption of processed and unhealthy food, lack of physical activity and lack of awareness on the risks of obesity. As a result, the demand for anti-obesity drugs is bound to increase in the future thus, driving market growth.

Obesity is a major health problem worldwide which is caused from leading a sedentary lifestyle and consumption of unhealthy food. Though various anti-obesity drugs have been approved and are available in the USA, European Union, Australia, and Japan to treat obesity and overweight. It has been observed that these drugs have various adverse effects on patients undergoing treatment for obesity. Adverse effects include low blood pressure and blood glucose, incontinence, insomnia, nausea, diarrhea and others. For instance, Sibutramine and its combination drugs sold under various brands was recalled in various countries due to various side effects including heart attack in consumers. These factors restraint the growth of anti-obesity drugs market.

Pharmaceutical industry is witnessing an increase in the number of mergers and acquisition among companies developing drugs for metabolic disorders such as obesity, diabetes and others. This is a strategy of pharmaceutical companies to strengthen their drug portfolio in metabolic diseases and launch safe and effective drugs in the market. For instance, in 2018, Evotec AG and Novo Nordisk entered into a strategic alliance to be able to discover and develop drug molecules to treat metabolic disorders including obesity, diabetes and other associated disorders.

Major players in the anti-obesity drugs market are F. Hoffmann-La Roche AG, , GlaxoSmithKline PLC, , Boehringer Ingelheim GmbH, and Pfizer Inc.

Smart pills are used to deliver medication and are equipped with electronic sensors that emit signals to be captured by patches or smartphones when they are swallowed. These pills ensure drug regimen compliance and help track medication adherence of patients. The main applications of smart pills are capsule endoscopy, patient monitoring, and drug delivery, patient monitoring involves the repeated or continuous observations or measurements of the patient parameters. These pills are used to target the esophagus, stomach, small intestine, and large intestine to treat diseases such as esophageal diseases, colon diseases, small bowel diseases, and others. Smart pills are used by various end-users such as hospitals, diagnostic centres, and research institutes. The smart pills market research report is one of a series of new reports from The Business Research Company that provides smart pills market statistics, including smart pills industry global market size, regional shares, competitors with a smart pills market share, detailed smart pills market segments, market trends and opportunities, and any further data you may need to thrive in the smart pills industry. This smart pills market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global smart pills market size will grow from $4.48 billion in 2022 to $4.98 billion in 2023 at a compound annual growth rate (CAGR) of 11.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global smart pills market size is expected to grow to $7.61 billion in 2027 at a CAGR of 11.2%. The growing preference for non-invasive procedures is driving the smart pills market. The non-invasive procedures are diagnostic and treatment procedures that do not require an incision on the body or removal of tissues for the treatment or diagnosis. Smart pill is a wireless, ingestible capsule that can be easily swallowed and has a wide range of applications in capsule endoscopy, drug delivery, and patient monitoring. For instance, smart pills have key applications in diagnostic imaging such as capsule endoscopy. The capsule endoscopy is a diagnostic procedure in which a smart pill (capsule enclosed micro-camera) is swallowed and images of the esophagus, stomach, and small intestine can be taken as the device pass through your gastrointestinal (GI) tract. Smart pills have revolutionized the diagnosis of gastrointestinal disorders and could replace conventional diagnostic techniques such as endoscopy. Therefore, non-invasive procedures are driving the smart pills market during the period. The high cost of smart pills associated with technological advancement will act as a restraint to the market growth. The utilization of advanced technologies including software up-gradation and innovative systems, and the integration of microchips contribute to the high manufacturing costs of the smart pills. Smart pills are a combination of drug and device technology. A smart pill is an innovative method of drug delivery, which involves the use of sensors and cameras embedded into tiny edible devices. Such medical devices ensure better diagnostics, monitoring, and treatment of life-threatening medical conditions by allowing doctors to monitor their patients’ body functions in real-time. However, the high cost of smart pills led to the limited utilization of products in underdeveloped countries. Thus, the high cost is considered as one of the factors that restrain the growth of the small pills market. Extensive research and development are being carried out on the use of miniature chips such as Addressable Transmitters Operated as Magnetic Spins (ATOMS) which can be used as smart pills. ATOMS are silicon chip devices that use the principle of magnetic resonance imaging (MRI) to determine the location of atoms in a patient’s body using magnetic fields. ATOMS can be used in ingestible smart pills to diagnose and treat diseases from within the body. The devices can be used to monitor a patient’s gastrointestinal tract, blood, or brain. They also could measure factors that indicate the health of a patient such as pH, temperature, pressure, and sugar concentrations, and relay that information to doctors. The devices could even be instructed to release drugs. For instance, scientists at Caltech (California Institute of Technology) have developed a miniature medical chip that can be used as a smart pill. Major players in the smart pills market are Medtronic PLC., Olympus Medical Technology, CapsoVision, Inc., Novartis AG, Proteus Pharmaceuticals, Philips Healthcare, Microchips, Bio-Images Drug Delivery (BDD) Limited, Given Imaging, Inc., and Vitality. North America was the largest region in the smart pills market in 2022. Western Europe was the second-largest region in the global smart pills market. The regions covered in the global smart pills market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the smart pills market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The smart pills market consists of sales of instruments that are used in applications such as capsule endoscopy, drug delivery, and patient monitoring. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global smart pills market is segmented - 1) By Application: Capsule Endoscopy, Patient Monitoring, Drug Delivery 2) By End User: Hospital, Diagnostic Center, Research Institute 3) By Target Area: Esophagus, Stomach, Small Intestine, Large Intestine 4) By Disease Indication: Esophageal Diseases, Colon Diseases, Small bowel Diseases, and Other Disease Indications

Oral contraceptive pills refer to a contraceptive tablet that contains hormones that prevent the release of eggs from the ovaries. Oral contraceptives typically contain progestin and oestrogen. Also known as the "birth control pill," it comprises hormones that prevent the emergence of eggs from the ovaries. Most oral contraceptives involve estrogen and progestin.   The oral contraceptive pills market by type into the combination, progestin-only, others; by category into generic, branded; by distribution channel into hospital pharmacy, retail pharmacy, clinics, online channel, public channel and NGO, others. The oral contraceptive pills market research report is one of a series of new reports from The Business Research Company that provides oral contraceptive pills market statistics, including oral contraceptive pills industry global market size, regional shares, competitors with an oral contraceptive pills market share, detailed oral contraceptive pills market segments, market trends and opportunities, and any further data you may need to thrive in the oral contraceptive pills industry. This oral contraceptive pills market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global oral contraceptive pills market grew from $20.13 billion in 2022 to $21.61 billion in 2023 at a compound annual growth rate (CAGR) of 7.35%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The oral contraceptive pills market size is expected to grow to $36.09 billion in 2027 at a CAGR of 13.68%. The high incidence of unintended pregnancies is expected to drive the growth of the oral contraceptive pills market over the coming years. Unintended pregnancy is a pregnancy that is always unwanted, such as a pregnancy where no children have been planned. The University of California, San Francisco (UCSF) study shows that the rates of unwanted pregnancy and abortion declined substantially when women received a one-year prescription of oral contraceptives. According to the World Health Organization (WHO), 74 million women living in low-middle-income economies register unplanned pregnancies every year globally. The WHO’s research noticed that 4,794 women had unplanned pregnancies after they had discontinued using contraceptives. Therefore, the need to avoid unintended pregnancies drives the growth of the oral contraceptive pills market. The side effects associated with the use of contraceptive drugs are expected to hinder the growth of the oral contraceptive pills market over the forecast period. An oral contraceptive pill is a hormonal procedure to avoid childbirth. The side effects vary between people and the type of pill consumed. Breast tenderness, headaches, spotting, and nausea are some prominent side effects of oral contraceptive pills. Depo-Provera, an implantable contraceptive, is known to provide the most severe side effects. Research has indicated that Depo-Provera and Depo-SubQ Provera 104 can trigger bone mineral density loss. The U.S. Food and Drug Administration (FDA) attached strict notices to the injection kit saying Depo-Provera and Depo-SubQ Provera 104 could not be used for more than 2 years, attributing to their side effects. The notice also suggests that the use of these medications may increase the risk of osteoporosis and bone disorders later in life. Hence, the side effects associated with the use of contraceptive drugs hamper the growth of the oral contraceptive pill market. Major institutes and companies operating in the oral contraceptive pill sector are focusing on developing innovative solutions for oral contraceptive pills. For instance, in July 2022, HRA Pharma, a France based innovative healthcare company, developed an over the-counter birth control pill called "Opill." HRA Pharma has submitted an application to the Food and Drug Administration in the United States. Opil is a progestin-based contraceptive that helps people access contraception without facing any difficulty. In January 2020, Theramex, a speciality pharmaceutical company for women announced the acquisition of rights to Zoely®, a patented oral contraceptive from Merck &Co for an undisclosed amount. This acquisition aids Theramex in global expansion and adding innovative treatment options for women to its portfolio. Merck & Co. is a US-based multinational pharmaceutical company that has oral contraceptives in its product portfolio. Major players in the contraceptive pills market are Teva Pharmaceutical Industries Ltd., Bayer AG, Syzygy Healthcare, Mankind Pharma Ltd., Pfizer Inc., Piramal Enterprises Ltd., Ferring B.V, Merck & Co. Inc., Johnson & Johnson, and Lupin Pharmaceuticals Inc. North America was the largest region in the oral contraceptive pills market in 2022. The Middle East is expected to be the largest growing region in the forecast period. The regions covered in the contraceptive pills market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the contraceptive pills market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The oral contraceptive pills market consists of sales of combined estrogen-progesterone, progesterone-only, and continuous or extended use pill. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global oral contraceptive pills market is segmented - 1) By Type: Combination, Progestin Only, Other Types 2) By Category: Generic, Branded 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Clinics, Online Channel, Public Channel And NGO, Other Distribution Channels

Weight loss supplements refer to dietary supplements that aid in weight loss by preventing the absorption of fat or carbs, reducing hunger, or accelerating metabolism. However, there is few scientific proof that diet pills are effective. These supplements boost metabolism and thermogenesis while decreasing macronutrient absorption, hunger, body fat, and weight. The main type of weight loss supplements includes liquid, powder, softgels, pills, and other types. A soft gel is a customized capsule that serves as an oral dosage form for medicine. The shells used in soft gels are made up of water, an opacifier, and a plasticizer like glycerin or sorbitol. The ingredients used in weight loss supplements include vitamins & minerals, amino acids, and natural extracts/botanicals. They are used by users age groups ranging from under 18 years, 18 to 40 years, 40 to 50 years, and above 50 years, and they are distributed through offline and online channels. The weight loss supplements market research report is one of a series of new reports from The Business Research Company that provides weight loss supplements market statistics, including weight loss supplements industry global market size, regional shares, competitors with a weight loss supplements market share, detailed weight loss supplements market segments, market trends and opportunities, and any further data you may need to thrive in the weight loss supplements industry. This weight loss supplements market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global weight loss supplements market size grew from $34.5 billion in 2022 to $39.18 billion in 2023 at a compound annual growth rate (CAGR) of 13.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The weight loss supplements market size is expected to grow to $65.16 billion in 2027 at a CAGR of 13.6%. The growing obese population is driving the growth of the weight loss supplements market. Obesity refers to the abnormal or excessive accumulation of fat, which might impair the health of individuals. In recent years, obesity has become a public health challenge across the globe, with a substantial contribution to global mortality and morbidity. The growing obese population is predicted to boost demand for weight loss supplements as these are widely adopted by individuals as healthy options to reduce weight. For instance, according to the World Health Organization (WHO), over 1 billion people globally are obese currently (2022), of that, 650 million are adults, 340 million are adolescents and 39 million are children. By 2025, around 167 million people; adults and children will become less healthy as they are overweight or obese. Thus, the growing obese population is expected to boost demand for weight loss supplements during the forecast period. The development of new production technologies and innovative products is a key trend gaining popularity in the weight loss supplements market. Major companies operating in the weight loss supplements market are focused on developing innovative weight loss supplements to meet fast-growing end customer demands and strengthen their position in the market. For instance, Nature's Formulas, a US-based supplement company has developed BioFit, an innovative, industry-leading probiotic weight loss supplement manufactured from natural ingredients. This product includes natural ingredients and 800 milligrams of microbes that can survive harsh stomach acids to quickly improve digestion, increase energy, and speed up fat loss with no side effects. The company has developed this product to target and help customers lose body weight without following strict diet plans, exercise, or weight-reducing surgeries. In January 2022, Solace Nutrition, a US-based medical nutrition company acquired the assets of R-Kane Nutritionals for an undisclosed amount. This acquisition of assets helps Solace Nutrition to create synergy between both brands and enhance its growth while providing a presence in an adjacent nutrition market. R-Kane Nutritionals is a US-based company that specializes in high protein meal replacement products for weight management. Major players in the weight loss supplements market are Glanbia PLC, GlaxoSmithKline PLC, Herbalife Nutrition Ltd., Abbott, Kellogg Company, Nestle, Kraft Heinz Company, Amway Corp, Ajinomoto Co Inc., Nutratech Ltd., Shaklee Corporation, Transparent Labs, Ultimate Life Ltd., and Vitaco. Asia-Pacific was the largest region in the weight loss supplements market in 2022, and it is also expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the weight loss supplements market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The weight loss supplements market consists of sales of chromium picolinate, glucomannan, and conjugated linoleic acid (CLA). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global weight loss supplements market is segmented - 1) By Type: Liquid, Powder, Softgels, Pills, Other Types 2) By Ingredents: Vitamins & Minerals, Amino Acids, Natural Extracts/Botanicals 3) By Distribution: Offline Channel, Online Channel 4) By End User: Under 18 years, 18 to 40 years, 40 to 50 years, Above 50 years

Personal services refer to those agencies that provide physical day-to-day household and individual assistance services to people. Personal services are provided to eligible beneficiaries to help them stay in their own homes and communities rather than live in institutional settings, such as nursing homes. The main types of personal services are personal care services, death care services, dry-cleaning, laundry services, other personal services, and private household services. Personal care services are hands-on services that help a person with essential daily chores that they are unable to do on their own. The different modes include online, and offline and are distributed through various channels such as specialty retail stores, supermarkets/hypermarkets, convenience stores, pharmacies/drug stores, online retail channels, and others. The personal services market research report is one of a series of new reports from The Business Research Company that provides personal services market statistics, including the personal services industry global market size, regional shares, competitors with a personal services market share, detailed personal services market segments, market trends and opportunities, and any further data you may need to thrive in the personal services industry. This personal services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global personal services market grew from $1,150.72 billion in 2022 to $1,240.07 billion in 2023 at a compound annual growth rate (CAGR) of 7.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The personal services market is expected to grow to $1,632.08 billion in 2027 at a CAGR of 7.1%. The personal services market's growth is expected to be aided by a stable economic growth forecast in many developed and developing countries. According to the International Monetary Fund (IMF), the global real GDP growth reached 3.7% in 2019 and 2020 and is expected to reach 3.6% from 2021 to 2023. Recovering commodity prices, after a significant decline in the historic period is further expected to aid the market growth. Developed economies are also expected to register stable growth during the forecast period. Additionally, emerging markets are expected to continue to grow slightly faster than developed markets in the forecast period. For instance, according to official data from the World Bank, the GDP of India increased to reach $3173.40 billion in 2021, compared to $2667.69 billion in 2020. Stable economic growth is expected to increase disposable incomes, driving the demand for personal services. The outbreak of COVID-19 disease (COVID-19) has acted as a massive restraint on the personal services market in 2020 as the need for services offered by these establishments declined due to lockdowns imposed by governments globally. COVID-19 is an infectious disease with flu-like symptoms including fever, cough, and difficulty in breathing. The virus was first identified in 2019 in Wuhan, Hubei province of the People's Republic of China, and spread globally including Western Europe, North America, and Asia. Steps by national governments to contain the transmission have resulted in a decline in economic activity with countries entering a state of 'lockdown' and the outbreak had a negative impact on businesses throughout 2020 and into 2021. However, it is expected that the personal services market will recover from the shock across the forecast period as it is a 'black swan event and not related to ongoing or fundamental weaknesses in the market or the global economy. Personal care service companies such as beauty salons, and spas are increasingly marketing their services through online platforms. These websites or applications allow customers to book appointments with beauticians who provide services such as haircuts, styling, makeup, massage, and others at the customer's premises. For instance, Lisa, an online platform offers haircuts, massages, manicures, and others at home upon making a prior booking. Other such online personal care service platforms include Glamsquad, Urbanclap, Luxit, and Glamazon. Major companies in the personal services market include Service Corporation International, Elis SA, Fantastic Sams, Weight Watchers International Inc., Spotless Group Holdings Ltd., Tivity Health, Dignity plc, Regis Corporation, and ProSiebenSat.1 Media SE and CSC Serviceworks Holdings Inc. Asia-Pacific was the largest region in the personal services market in 2022. North America was the second-largest region in the personal services market. The regions covered in the personal services market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the personal services market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The personal services market consists of revenues earned by entities that provide personal services to individuals, households, and businesses such as beauty salons, diet and weight-reducing centers, spas & massage parlours, funeral homes, and funeral services, cemeteries and crematories, dry-cleaning and laundry services (except coin-operated), photofinishing, parking lots and garages. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global personal services market is segmented - 1) By Type: Personal Care Services, Death Care Services, Dry-Cleaning And Laundry Services, Other Personal Services, Private Household Services 2) By Mode: Online, Offline 3) By Distribution Channel: Specialist Retail Stores, Supermarkets/Hypermarkets, Convenience Stores, Pharmacies/Drug Stores, Online Retail Channels, Other Distribution Channels Subsegments Covered: Beauty Salons, Diet And Weight Reducing Centers, Spas & Massage Parlors, Other Personal Care Services, Funeral Homes And Funeral Services, Cemeteries And Crematories, Coin-Operated Laundries And Drycleaners, Dry-Cleaning And Laundry Services (except Coin-Operated), Linen And Uniform Supply, Pet Care (except Veterinary) Services, Photofinishing, Parking Lots And Garages, All Other Personal Services, In-house Workers, Outside Workers

The antacids drugs refer to the drugs that are used to neutralize stomach acid, and treat acid reflux, heartburn, and indigestion. Antacids are medications that counteract (neutralise) your stomach's acid to ease heartburn and indigestion. They are available without a prescription from pharmacies and stores and come in liquid or chewable tablet form. It includes drug classes such as proton pump inhibitors, H2 antagonists, surgical simulators, and acid neutralizers in the form of tablets, liquid, or powder. The main classes of antacids are proton pump inhibitors, H2 antagonists, acid neutralizers, and pro-motility agents. Proton-pump inhibitors are a type of drug that reduces stomach acid production significantly and for a long time. They accomplish this by blocking the H+/K+ ATPase proton pump in the stomach in an irreversible manner. The different types of formulations include tablets, liquids, powders, and others and are distributed through various channels such as hospital pharmacies, retail pharmacies, and others. The antacids market research report is one of a series of new reports from The Business Research Company that provides antacids market statistics, including antacids industry global market size, regional shares, competitors with an antacids market share, detailed antacids market segments, market trends, and opportunities, and any further data you may need to thrive in the antacids industry. This antacids market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global antacids market size will grow from $9.19 billion in 2022 to $9.56 billion in 2023 at a compound annual growth rate (CAGR) of 4.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global antacids market size is expected to grow to $10.65 billion in 2027 at a CAGR of 2.7%. Poor lifestyle choices resulting in a higher prevalence of acidity are an important driver for the growth of the antacids market. Poor lifestyle choices involve deskbound jobs, poor quality of sleep, and irregular dietary habits, which result in an increase in the acidity level of the stomach and lead to gastroesophageal reflux disease. According to the American College of Gastroenterology, around 60 million Americans suffer from gastroesophageal reflux disease. This drives the demand for antacids. The side effects related to antacids are a major restraint for the antacids market. Some of the common side effects of antacids include dose-dependent rebound hyperacidity and milk-alkali syndrome. Antacids containing aluminum hydroxide may also cause side effects such as constipation, aluminum-intoxication, osteomalacia, and hypophosphatemia. In addition, antacids when consumed with other acidic drugs might lead to absorption of both the drugs resulting in reduced efficiency of both the drugs. Mouth-melting antacid is an emerging trend in the antacid market. Antacids were available in tablet, liquid, and powder form until now; however, researchers have now come up with mouth-melting antacids which are made up of micro-mouth melting granules that easily melt in the mouth. These granules present in the antacids act in the form of effervescent. An example of a mouth-melting instant relief antacid is Sunpharma's 'Pepmelt', which integrates the effects of herbal constituents present in it with the contemporary mouth-melting technology. The manufacturers of antacids in the USA need to comply with CFR - Code of Federal Regulations Title 21 laid down by the FDA. According to these regulations, an over-the-counter (OTC) antacid product in a form suitable for oral administration is recognized as safe and effective only if it meets the conditions related to active ingredients established by the regulatory body. Major players in the antacids market are GlaxoSmithKline PLC., Pfizer Inc., Bayer AG, Dr. Reddy's Laboratories Ltd., and AstraZeneca PLC, Boehringer Ingelheim GmbH, Sun Pharmaceuticals Industries Ltd., Takeda Pharmaceutical Company Limited, Abbott Laboratories, and WellSpring Pharm. North America was the largest region in the antacids market in 2022. The Middle East is expected to be the fastest-growing region in the global antacids market. The regions covered in the global antacids market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the antacids market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The antacids market consists of sales of Alka Seltzer, Maalox, Mylanta, Rolaids, Tums, and Pepto-Bismol. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global antacids market is segmented - 1) Drug Class: Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Pro-Motility Agents 2) Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels 3) By Formulation Type: Tablet, Liquid, Powder, Other Formulation Types

Anemia and Other Blood Disorder Drugs refer to the medications or drugs that are used to treat anemia and other blood disorder diseases. It refers to a blood condition that develops when a medication prompts the body's immune system to begin attacking its own red blood cells. Hemolysis, a process that causes red blood cells to degrade earlier than usual, is brought on by this. The main types of anemia and other blood disorder drugs are iron deficiency anemia, chronic kidney disease anemia, sickle cell anemia, and aplastic anemia. Iron deficiency anemia is a common kind of anemia in which the blood does not contain enough healthy red blood cells. The oxygen-carrying red blood cells transport oxygen to the body's cells. The different types of anemia include microcytic (Low MCV), normocytic (Normal MCV), and macrocytic (High MCV) and involve various routes of administration such as oral, and injectable. It is distributed through hospitals pharmacies, online pharmacies, and pharmacy. The anemia and other blood disorder drugs market research report are one of a series of new reports from The Business Research Company that provides anemia and other blood disorder drugs market statistics, including anemia and other blood disorder drugs industry global market size, regional shares, competitors with anemia and other blood disorder drugs market share, detailed anemia and other blood disorder drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anemia and other blood disorder drugs industry. This anemia and other blood disorder drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global anemia and other blood disorder drugs market size will grow from $11.14 billion in 2022 to $11.87 billion in 2023 at a compound annual growth rate (CAGR) of 6.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global anemia and other blood disorder drugs market size is expected to grow to $14.80 billion in 2027 at a CAGR of 5.7%. The increasing prevalence of anemia among the global population acts as a strong driving factor for the market. Unhealthy lifestyles, changing dietary habits and increased stress levels increased the cases of anemia worldwide. For instance, anemia was found to be the most frequent disease in the elderly population (> 65 years of age), reaching a prevalence rate of around 17%. the World Bank reported that anemia is the 8th leading cause of disease among women and the young population. Growth in the prevalence rate of anemia drives the market. There has been an increase in the use of biologics for treating anemia and other blood disorders. Biologics are composed of protein, sugar, nucleic acids, or a combination of these substances or might be derived from living organisms like humans, animals, or microorganisms or that may contain components of living organisms. The growth in the use of biologics over the drugs restricts the market resulting in the decline of the number of drugs being used for the treatment of anemia& other blood disorders. For example, Hospira, a medical device and pharmaceutical company, submitted its first biologics license application to FDA for the approval of a drug that treats anemia. Moreover, the FDA approved the first Epoetin Alfa biosimilar for the treatment of anemia caused by chronic kidney disease, chemotherapy, or the use of zidovudine in patients with HIV infection. The increase in the use of biologics will hamper the growth of the market. Companies in the anemia and other blood disorder drugs market are collaborating with other companies to develop and commercialize a specific kind of drug by sharing the knowledge, technology, and cost. Such collaborations are also helpful to the companies in case of expiring licenses and a stringent regulatory environment. For example, in 2020, Akebia Therapeutics announced collaboration with Tobacco Inc. to treat adult patients with iron deficiency anemia. Another such example is, Akebia Therapeutics Inc. and Otsuka Pharmaceutical Co. Ltd. agreed to manufacture and commercialize vadadustat, an oral HIF stabilizer, used for the treatment of anemia. The anemia and other blood disorder drugs market is governed by several regulatory bodies that regulate their functioning by carrying out quality checks for that drug before it can be launched in the market. For instance, the U.S. Food & Drug Administration (FDA) requires every pharmaceutical company to get its drugs examined by the concerned authority. FDA sorts to a Risk Evaluation and Mitigation Strategy (REMS) for determining the safety and quality standards of the drug and grants approvals only if the standards are up to the mark. In October 2022, Pfizer, a US-based pharmaceutical company acquired Global Blood Therapeutics Inc. for an undisclosed amount. Through this acquisition, Pfizer expanded its portfolio in the development of drugs and brought various potential best-in-class treatments to people living with sickle cell disease. Global Blood Therapeutics Inc. is a US-based biotech company operating in anemia and other blood disorder drugs. Major players in the anemia and other blood disorder drugs market are Amgen Inc., GlaxoSmithKline PLC., Akebia Therapeutics, Bayer AG, Pfizer Inc., Regenbiopharma, Hoffmann-La Roche Ltd., Merck Sharp &Dohme Corp., Novartis AG and Janssen Pharmaceutical. North America was the largest region in the anemia and other blood disorder drugs market in 2022. Middle East is expected to be the fastest-growing region in the global anemia and other blood disorder drugs market during the forecast period. The regions covered in the global anemia and other blood disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the anemia and other blood disorder drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The anemia and other blood disorder drugs market consists of sales of folate analogues, multivitamin and mineral supplements, iron supplements, and erythropoiesis-stimulating agents. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global anemia and other blood disorder drugs market is segmented - 1) By Type: Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia 2) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy 3) By Route of Administration: Oral, Injectable 4) By Anemia Type: Microcytic (Low MCV), Normocytic (Normal MCV), Macrocytic (High MCV)